Drug Development Pipeline
MS1819-SD is a non-porcine (not pig-derived) enzyme for individuals with CF who have exocrine pancreatic insufficiency. It is a man-made version of the lipase enzyme from the yeast Yarrowia lipolytica. This drug does not contain any animal products.
In 2018, a phase 2a study of MS1819-SD was conducted in people with chronic pancreatitis. The study showed that MS1819-SD was safe and may potentially improve fat absorption.
A phase 2 study in people with CF is currently enrolling. This study will compare MS1819-SD to currently available porcine-derived enzymes.
This program is sponsored by AzurRx Biopharma. It is being conducted within the Therapeutics Development Network (TDN).
Recent MS1819-SD Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More